

Nicoline Hoogerbrugge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8327038/publications.pdf>

Version: 2024-02-01

308
papers

16,840
citations

18887

64
h-index

23173

116
g-index

314
all docs

314
docs citations

314
times ranked

19816
citing authors

#	ARTICLE	IF	CITATIONS
1	Healthcare professionals' perspectives on implementation of universal tumor DNA testing in ovarian cancer patients: multidisciplinary focus groups. <i>Familial Cancer</i> , 2023, 22, 1-11.	0.9	3
2	Probability of detecting germline BRCA1/2 pathogenic variants in histological subtypes of ovarian carcinoma. A meta-analysis. <i>Gynecologic Oncology</i> , 2022, 164, 221-230.	0.6	11
3	Genetic Cancer Susceptibility in Adolescents and Adults 25 Years or Younger With Colorectal Cancer. <i>Gastroenterology</i> , 2022, 162, 969-974.e6.	0.6	2
4	Gastric cancer genetic predisposition and clinical presentations: Established heritable causes and potential candidate genes. <i>European Journal of Medical Genetics</i> , 2022, 65, 104401.	0.7	10
5	Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors. <i>Supportive Care in Cancer</i> , 2022, 30, 3409-3418.	1.0	1
6	Risk of Peritoneal Carcinomatosis After Risk-Reducing Salpingo-Oophorectomy: A Systematic Review and Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2022, 40, 1879-1891.	0.8	25
7	Solving the genetic aetiology of hereditary gastrointestinal tumour syndromes: a collaborative multicentre endeavour within the project Solve-RD. <i>European Journal of Medical Genetics</i> , 2022, 65, 104475.	0.7	2
8	Germline MBD4 deficiency causes a multi-tumor predisposition syndrome. <i>American Journal of Human Genetics</i> , 2022, 109, 953-960.	2.6	23
9	Catch them if you are aware: PTEN postzygotic mosaicism in clinically suspicious patients with PTEN Hamartoma Tumour Syndrome and literature review. <i>European Journal of Medical Genetics</i> , 2022, , 104533.	0.7	4
10	The yield and effectiveness of breast cancer surveillance in women with PTEN Hamartoma Tumor Syndrome. <i>Cancer</i> , 2022, 128, 2883-2891.	2.0	4
11	A review on age-related cancer risks in PTEN hamartoma tumor syndrome. <i>Clinical Genetics</i> , 2021, 99, 219-225.	1.0	42
12	Somatic Nonepigenetic Mismatch Repair Gene Aberrations Underly Most Mismatch Repair-Deficient Lynch-Like Tumors. <i>Gastroenterology</i> , 2021, 160, 1414-1416.e3.	0.6	13
13	No signs of subclinical atherosclerosis after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. <i>Journal of Cardiology</i> , 2021, 77, 570-575.	0.8	3
14	RNF43 mutation analysis in serrated polyposis, sporadic serrated polyps and Lynch syndrome polyps. <i>Histopathology</i> , 2021, 78, 749-758.	1.6	10
15	Continue rare cancers collaboration with European Reference Networks after Brexit. <i>Lancet</i> , The, 2021, 397, 793.	6.3	2
16	European Reference Networks: challenges and opportunities. <i>Journal of Community Genetics</i> , 2021, 12, 217-229.	0.5	21
17	Breast cancer surveillance in women with PTEN Hamartoma Tumour Syndrome (PHTS). <i>Breast</i> , 2021, 56, S38.	0.9	0
18	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome. <i>Cancers</i> , 2021, 13, 2345.	1.7	3

#	ARTICLE	IF	CITATIONS
19	A mosaic PIK3CA variant in a young adult with diffuse gastric cancer: case report. <i>European Journal of Human Genetics</i> , 2021, 29, 1354-1358.	1.4	9
20	Solve-RD: systematic pan-European data sharing and collaborative analysis to solve rare diseases. <i>European Journal of Human Genetics</i> , 2021, 29, 1325-1331.	1.4	49
21	Universal genetic assessment for women with ovarian cancer not yet achieved: the promises of universal tumor DNA testing. <i>Gynecologic Oncology Reports</i> , 2021, 38, 100825.	0.3	0
22	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 1014-1022.	5.1	58
23	Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers. <i>JAMA Oncology</i> , 2021, 7, 1203.	3.4	27
24	Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy. <i>Gynecologic Oncology</i> , 2021, 163, 371-377.	0.6	2
25	Red flags for early recognition of adult patients with PTEN Hamartoma Tumour Syndrome. <i>European Journal of Medical Genetics</i> , 2021, 64, 104364.	0.7	7
26	Overview of hereditary breast and ovarian cancer (HBOC) guidelines across Europe. <i>European Journal of Medical Genetics</i> , 2021, 64, 104350.	0.7	22
27	Universal Tumor DNA BRCA1/2 Testing of Ovarian Cancer: Prescreening PARPi Treatment and Genetic Predisposition. <i>Journal of the National Cancer Institute</i> , 2020, 112, 161-169.	3.0	47
28	Response to Tomao, Panici, and Tomao. <i>Journal of the National Cancer Institute</i> , 2020, 112, 425-425.	3.0	0
29	Microsatellite instability screening in colorectal adenomas to detect Lynch syndrome patients? A systematic review and meta-analysis. <i>European Journal of Human Genetics</i> , 2020, 28, 277-286.	1.4	22
30	“Patient Journeys” improving care by patient involvement. <i>European Journal of Human Genetics</i> , 2020, 28, 141-143.	1.4	18
31	Candidate Gene Discovery in Hereditary Colorectal Cancer and Polyposis Syndromes—Considerations for Future Studies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8757.	1.8	7
32	Hereditary diffuse gastric cancer: updated clinical practice guidelines. <i>Lancet Oncology</i> , The, 2020, 21, e386-e397.	5.1	237
33	Monoallelic NTHL1 Loss-of-Function Variants and Risk of Polyposis and Colorectal Cancer. <i>Gastroenterology</i> , 2020, 159, 2241-2243.e6.	0.6	20
34	Recommendations on Surveillance for Differentiated Thyroid Carcinoma in Children with PTEN Hamartoma Tumor Syndrome. <i>European Thyroid Journal</i> , 2020, 9, 234-242.	1.2	14
35	Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. <i>European Journal of Human Genetics</i> , 2020, 28, 1387-1393.	1.4	63
36	Evaluation of yield and experiences of age-related molecular investigation for heritable and nonheritable causes of mismatch repair deficient colorectal cancer to identify Lynch syndrome. <i>International Journal of Cancer</i> , 2020, 147, 2150-2158.	2.3	15

#	ARTICLE	IF	CITATIONS
37	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 368-378.	1.1	24
38	<i>TRIM28</i> haploinsufficiency predisposes to Wilms tumor. <i>International Journal of Cancer</i> , 2019, 145, 941-951.	2.3	45
39	Effect of PTEN inactivating germline mutations on innate immune cell function and thyroid cancer-induced macrophages in patients with PTEN hamartoma tumor syndrome. <i>Oncogene</i> , 2019, 38, 3743-3755.	2.6	20
40	Addition of a 161-SNP polygenic risk score to family history-based risk prediction: impact on clinical management in non- <i>BRCA1/2</i> breast cancer families. <i>Journal of Medical Genetics</i> , 2019, 56, 581-589.	1.5	35
41	De Novo and Inherited Pathogenic Variants in <i>KDM3B</i> Cause Intellectual Disability, Short Stature, and Facial Dysmorphism. <i>American Journal of Human Genetics</i> , 2019, 104, 758-766.	2.6	34
42	Romidepsin suppresses monosodium urate crystal-induced cytokine production through upregulation of suppressor of cytokine signaling 1 expression. <i>Arthritis Research and Therapy</i> , 2019, 21, 50.	1.6	25
43	Mutational Signature Analysis Reveals <i>NTHL1</i> Deficiency to Cause a Multi-tumor Phenotype. <i>Cancer Cell</i> , 2019, 35, 256-266.e5.	7.7	123
44	Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing <i>BRCA1/2</i> testing without pretest genetic counseling. <i>Acta Oncologica</i> , 2019, 58, 175-181.	0.8	6
45	Boosting care and knowledge about hereditary cancer: European Reference Network on Genetic Tumour Risk Syndromes. <i>Familial Cancer</i> , 2019, 18, 281-284.	0.9	17
46	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. <i>Translational Oncology</i> , 2019, 12, 361-367.	1.7	33
47	High Yield of Pathogenic Germline Mutations Causative or Likely Causative of the Cancer Phenotype in Selected Children with Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1594-1603.	3.2	52
48	A patient decision aid for risk-reducing surgery in premenopausal <i>BRCA1/2</i> mutation carriers: Development process and pilot testing. <i>Health Expectations</i> , 2018, 21, 659-667.	1.1	17
49	Role of germline aberrations affecting <i>CTNNA1</i> , <i>MAP3K6</i> and <i>MYD88</i> in gastric cancer susceptibility. <i>Journal of Medical Genetics</i> , 2018, 55, 669-674.	1.5	37
50	Peritoneal carcinomatosis after risk-reducing surgery in <i>BRCA1/2</i> mutation carriers. <i>Cancer</i> , 2018, 124, 952-959.	2.0	27
51	Self-compassion, physical fitness and climacteric symptoms in oophorectomized <i>BRCA1/2</i> mutation carriers. <i>Maturitas</i> , 2018, 108, 13-17.	1.0	3
52	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. <i>Gastrointestinal Endoscopy</i> , 2018, 87, 397-404.e2.	0.5	28
53	High demoralization in a minority of oophorectomized <i>BRCA1/2</i> mutation carriers influences quality of life. <i>Journal of Psychosomatic Obstetrics and Gynaecology</i> , 2018, 39, 96-104.	1.1	7
54	Increasing awareness and knowledge of lifestyle recommendations for cancer prevention in Lynch syndrome carriers: Randomized controlled trial. <i>Clinical Genetics</i> , 2018, 93, 67-77.	1.0	9

#	ARTICLE	IF	CITATIONS
55	Influence of Risk Category and Screening Round on the Performance of an MR Imaging and Mammography Screening Program in Carriers of the <i>BRCA</i> Mutation and Other Women at Increased Risk. <i>Radiology</i> , 2018, 286, 443-451.	3.6	48
56	<i>NTHL1</i> and <i>MUTYH</i> polyposis syndromes: two sides of the same coin?. <i>Journal of Pathology</i> , 2018, 244, 135-142.	2.1	63
57	Cancer Risks for <i>PMS2</i> -Associated Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2018, 36, 2961-2968.	0.8	147
58	The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI. <i>Breast Cancer Research</i> , 2018, 20, 84.	2.2	40
59	An online self-test added to colorectal cancer screening can increase the effectiveness of familial cancer risk assessment without increasing distress. <i>Colorectal Disease</i> , 2018, 20, 897-904.	0.7	2
60	Cancer prevention by aspirin in children with Constitutional Mismatch Repair Deficiency (CMMRD). <i>European Journal of Human Genetics</i> , 2018, 26, 1417-1423.	1.4	20
61	Online self-test identifies women at high familial breast cancer risk in population-based breast cancer screening without inducing anxiety or distress. <i>European Journal of Cancer</i> , 2017, 78, 45-52.	1.3	14
62	Surveillance of Women with the <i>BRCA</i> 1 or <i>BRCA</i> 2 Mutation by Using Biannual Automated Breast US, MR Imaging, and Mammography. <i>Radiology</i> , 2017, 285, 376-388.	3.6	61
63	Childhood neuroendocrine tumours: a descriptive study revealing clues for genetic predisposition. <i>British Journal of Cancer</i> , 2017, 116, 163-168.	2.9	16
64	Lifestyle Risk Factors for Breast Cancer in <i>BRCA</i> 1/2 Mutation Carriers Around Childbearing Age. <i>Journal of Genetic Counseling</i> , 2017, 26, 785-791.	0.9	6
65	Unraveling genetic predisposition to familial or early onset gastric cancer using germline whole-exome sequencing. <i>European Journal of Human Genetics</i> , 2017, 25, 1246-1252.	1.4	34
66	Self-compassion and climacteric symptoms in postmenopausal <i>BRCA</i> 1/2 mutation carriers. <i>Maturitas</i> , 2017, 100, 130.	1.0	0
67	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome. <i>Cancer Letters</i> , 2017, 403, 159-164.	3.2	37
68	Novel <i>BRCA</i> 1 and <i>BRCA</i> 2 Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas. <i>Human Mutation</i> , 2017, 38, 226-235.	1.1	55
69	Colorectal Cancer Risk in Patients With Lynch Syndrome and Inflammatory Bowel Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 454-458.e1.	2.4	20
70	Germline activating <i>TYK2</i> mutations in pediatric patients with two primary acute lymphoblastic leukemia occurrences. <i>Leukemia</i> , 2017, 31, 821-828.	3.3	35
71	A molecular inversion probe-based next-generation sequencing panel to detect germline mutations in Chinese early-onset colorectal cancer patients. <i>Oncotarget</i> , 2017, 8, 24533-24547.	0.8	12
72	Determinants of adherence to recommendations for cancer prevention among Lynch Syndrome mutation carriers: A qualitative exploration. <i>PLoS ONE</i> , 2017, 12, e0178205.	1.1	10

#	ARTICLE	IF	CITATIONS
73	Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriers. <i>Annals of Oncology</i> , 2016, 27, vi362.	0.6	4
74	Prevalence of germline mutations in the spindle assembly checkpoint gene BUB1B in individuals with early-onset colorectal cancer. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 855-863.	1.5	30
75	Opportunities for immunotherapy in microsatellite instable colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 1249-1259.	2.0	67
76	Prospective Dutch colorectal cancer cohort: an infrastructure for long-term observational, prognostic, predictive and (randomized) intervention research. <i>Acta Oncologica</i> , 2016, 55, 1273-1280.	0.8	62
77	Finding all BRCA pathogenic mutation carriers: best practice models. <i>European Journal of Human Genetics</i> , 2016, 24, S19-S26.	1.4	15
78	Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience. <i>Gynecologic Oncology</i> , 2016, 143, 113-119.	0.6	23
79	The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. <i>Cellular Oncology (Dordrecht)</i> , 2016, 39, 491-510.	2.1	34
80	Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers. <i>Obstetrics and Gynecology</i> , 2016, 127, 1054-1063.	1.2	21
81	Cardiovascular risk of BRCA1/2 mutation carriers: A review. <i>Maturitas</i> , 2016, 91, 135-139.	1.0	28
82	Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline. <i>Clinical Genetics</i> , 2016, 90, 105-117.	1.0	143
83	Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect. <i>Familial Cancer</i> , 2016, 15, 289-296.	0.9	13
84	Colorectal cancer risk variants at 8q23.3 and 11q23.1 are associated with disease phenotype in APC mutation carriers. <i>Familial Cancer</i> , 2016, 15, 563-570.	0.9	8
85	Recognition of genetic predisposition in pediatric cancer patients: An easy-to-use selection tool. <i>European Journal of Medical Genetics</i> , 2016, 59, 116-125.	0.7	125
86	High Satisfaction and Low Distress in Breast Cancer Patients One Year after BRCA Mutation Testing without Prior Face-to-Face Genetic Counseling. <i>Journal of Genetic Counseling</i> , 2016, 25, 504-514.	0.9	30
87	BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. <i>European Journal of Human Genetics</i> , 2016, 24, 881-888.	1.4	58
88	The effect of genotypes and parent of origin on cancer risk and age of cancer development in PMS2 mutation carriers. <i>Genetics in Medicine</i> , 2016, 18, 405-409.	1.1	15
89	Peer support and additional information in group medical consultations (GMCs) for BRCA1/2 mutation carriers: A randomized controlled trial. <i>Acta Oncologica</i> , 2016, 55, 178-187.	0.8	5
90	Identification of Novel Candidate Genes for Early-Onset Colorectal Cancer Susceptibility. <i>PLoS Genetics</i> , 2016, 12, e1005880.	1.5	52

#	ARTICLE	IF	CITATIONS
91	Abstract IA44: Cancer prevention: Dendritic cell enhanced immune responses towards neoantigens in patients with Lynch syndrome. , 2016, , .		0
92	Deleterious Germline BLM Mutations and the Risk for Early-onset Colorectal Cancer. Scientific Reports, 2015, 5, 14060.	1.6	67
93	Breast Self-examination Education for BRCA Mutation Carriers by Clinical Nurse Specialists. Clinical Nurse Specialist, 2015, 29, E1-E7.	0.3	11
94	Poor prognosis of constitutive γ -H2AX expressing triple-negative breast cancers is associated with telomere length. Biomarkers in Medicine, 2015, 9, 383-390.	0.6	17
95	Risk-reducing salpingectomy with delayed oophorectomy in BRCA1/2 mutation carriers: Patients' and professionals' perspectives. Gynecologic Oncology, 2015, 136, 305-310.	0.6	31
96	No effects of atorvastatin (10mg/d or 80mg/d) on nitric oxide, prostacyclin, thromboxane and oxidative stress in type 2 diabetes mellitus patients of the DALI study. Pharmacological Research, 2015, 94, 1-8.	3.1	11
97	Gastric cancer in three relatives of a patient with a biallelic IL12RB1 mutation. Familial Cancer, 2015, 14, 89-94.	0.9	14
98	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
99	Germline deletions in the tumour suppressor gene <i>FOCAD</i> are associated with polyposis and colorectal cancer development. Journal of Pathology, 2015, 236, 155-164.	2.1	28
100	Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline <i>CDH1</i> mutation carriers. Journal of Medical Genetics, 2015, 52, 361-374.	1.5	479
101	Highlights from the seventh European Multidisciplinary Colorectal Cancer Congress (EMCCC) 2014. Ecanermedicalscience, 2015, 9, 497.	0.6	0
102	How medical choices influence quality of life of women carrying a BRCA mutation. Critical Reviews in Oncology/Hematology, 2015, 96, 555-568.	2.0	22
103	Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1. Gastroenterology, 2015, 149, 897-906.e19.	0.6	70
104	Candidate colorectal cancer predisposing gene variants in Chinese early-onset and familial cases. World Journal of Gastroenterology, 2015, 21, 4136.	1.4	10
105	A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nature Genetics, 2015, 47, 668-671.	9.4	311
106	Improving recognition and referral of patients with an increased familial risk of colorectal cancer: results from a randomized controlled trial. Colorectal Disease, 2015, 17, 499-510.	0.7	10
107	Low prevalence of serrated polyposis syndrome in screening populations: a systematic review. Endoscopy, 2015, 47, 1043-1049.	1.0	28
108	Early salpingectomy (Tubectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer, 2015, 15, 593.	1.1	88

#	ARTICLE	IF	CITATIONS
109	Lynch Syndrome Caused by Germline <i>PMS2</i> Mutations: Delineating the Cancer Risk. <i>Journal of Clinical Oncology</i> , 2015, 33, 319-325.	0.8	177
110	Patient experiences with gene panels based on exome sequencing in clinical diagnostics: high acceptance and low distress. <i>Clinical Genetics</i> , 2015, 87, 319-326.	1.0	23
111	Candidate Genetic Modifiers for Breast and Ovarian Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 308-316.	1.1	22
112	<i>NTHL1</i> defines novel cancer syndrome. <i>Oncotarget</i> , 2015, 6, 34069-34070.	0.8	21
113	More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. <i>Familial Cancer</i> , 2014, 13, 143-51.	0.9	33
114	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers. <i>PLoS Genetics</i> , 2014, 10, e1004256.	1.5	47
115	Germline <i>MUTYH</i> gene mutations are not frequently found in unselected patients with papillary breast carcinoma. <i>Hereditary Cancer in Clinical Practice</i> , 2014, 12, 21.	0.6	4
116	A multiplex method for the detection of serum antibodies against in silico-predicted tumor antigens. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1251-1259.	2.0	6
117	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of <i>BRCA1</i> and <i>BRCA2</i> Dutch founder mutations. <i>Journal of Medical Genetics</i> , 2014, 51, 98-107.	1.5	74
118	Easy-to-Use Decision Aids for Improved Cancer Family History Collection and Use Among Oncology Practices. <i>Journal of Clinical Oncology</i> , 2014, 32, 3343-3343.	0.8	5
119	Easy-to-use online referral test detects most patients with a high familial risk of colorectal cancer. <i>Colorectal Disease</i> , 2014, 16, O26-34.	0.7	12
120	Relevance and efficacy of breast cancer screening in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers above 60 years: A national cohort study. <i>International Journal of Cancer</i> , 2014, 135, 2940-2949.	2.3	13
121	Colorectal cancer risk variants on 11q23 and 15q13 are associated with unexplained adenomatous polyposis. <i>Journal of Medical Genetics</i> , 2014, 51, 55-60.	1.5	21
122	Somatic Mutations in <i>MLH1</i> and <i>MSH2</i> Are a Frequent Cause of Mismatch-Repair Deficiency in Lynch Syndrome-Like Tumors. <i>Gastroenterology</i> , 2014, 146, 643-646.e8.	0.6	294
123	Fourfold increased detection of Lynch syndrome by raising age limit for tumour genetic testing from 50 to 70 years is cost-effective. <i>Annals of Oncology</i> , 2014, 25, 2001-2007.	0.6	26
124	<i>HNF4A</i> immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 464, 673-679.	1.4	26
125	<i>BRCA1/2</i> mutation carriers are potentially at higher cardiovascular risk. <i>Critical Reviews in Oncology/Hematology</i> , 2014, 91, 159-171.	2.0	31
126	<i>EPCAM</i> deletion carriers constitute a unique subgroup of Lynch syndrome patients. <i>Familial Cancer</i> , 2013, 12, 169-174.	0.9	100

#	ARTICLE	IF	CITATIONS
127	Germline Mutations in the Spindle Assembly Checkpoint Genes BUB1 and BUB3 Are Risk Factors for Colorectal Cancer. <i>Gastroenterology</i> , 2013, 145, 544-547.	0.6	86
128	Cost-Effectiveness of Screening Women With Familial Risk for Breast Cancer With Magnetic Resonance Imaging. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1314-1321.	3.0	57
129	Clinical utility gene card for: Hereditary diffuse gastric cancer (HDGC). <i>European Journal of Human Genetics</i> , 2013, 21, 891-891.	1.4	22
130	Breast cancer size estimation with MRI in BRCA mutation carriers and other high risk patients. <i>European Journal of Radiology</i> , 2013, 82, 1416-1422.	1.2	18
131	Can we test for hereditary cancer at 18 years when we start surveillance at 25? Patient reported outcomes. <i>Familial Cancer</i> , 2013, 12, 675-682.	0.9	15
132	Familial colorectal cancer risk assessment needs improvement for more effective cancer prevention in relatives. <i>Colorectal Disease</i> , 2013, 15, e175-85; discussion p.e185.	0.7	19
133	Identification of germline mutations in the cancer predisposing gene CDH1 in patients with orofacial clefts. <i>Human Molecular Genetics</i> , 2013, 22, 919-926.	1.4	55
134	Focusing on Patient Needs and Preferences May Improve Genetic Counseling for Colorectal Cancer. <i>Journal of Genetic Counseling</i> , 2013, 22, 118-124.	0.9	10
135	Comparability versus statistical correctness. <i>European Journal of Radiology</i> , 2013, 82, e908.	1.2	1
136	Added Value of Family History in Counseling About Risk of BRCA1/2 Mutation in Early-Onset Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 1406-1410.	1.2	4
137	Exome Sequencing of Germline DNA from Non-BRCA1/2 Familial Breast Cancer Cases Selected on the Basis of aCGH Tumor Profiling. <i>PLoS ONE</i> , 2013, 8, e55734.	1.1	29
138	A Nonsynonymous Polymorphism in <i>IRS1</i> Modifies Risk of Developing Breast and Ovarian Cancers in <i>BRCA1</i> and Ovarian Cancer in <i>BRCA2</i> Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1362-1370.	1.1	23
139	Risks of Less Common Cancers in Proven Mutation Carriers With Lynch Syndrome. <i>Journal of Clinical Oncology</i> , 2012, 30, 4409-4415.	0.8	262
140	Differences in Natural History between Breast Cancers in <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers and Effects of MRI Screening-MRISC, MARIBS, and Canadian Studies Combined. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1458-1468.	1.1	79
141	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	1.1	513
142	Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 425-431.	1.4	4
143	Rare variants in XRCC2 as breast cancer susceptibility alleles: Table 1. <i>Journal of Medical Genetics</i> , 2012, 49, 618-620.	1.5	49
144	Adequacy of family history taking in ovarian cancer patients: a population-based study. <i>Familial Cancer</i> , 2012, 11, 343-349.	0.9	12

#	ARTICLE	IF	CITATIONS
145	DNA-testing for BRCA1/2 prior to genetic counselling in patients with breast cancer: design of an intervention study, DNA-direct. BMC Women's Health, 2012, 12, 12.	0.8	9
146	Familial gastric cancer: detection of a hereditary cause helps to understand its etiology. Hereditary Cancer in Clinical Practice, 2012, 10, 18.	0.6	33
147	Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Familial Cancer, 2012, 11, 363-369.	0.9	71
148	Breast Cancer Risk and 6q22.33: Combined Results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. PLoS ONE, 2012, 7, e35706.	1.1	11
149	<i>CDH1</i> -related hereditary diffuse gastric cancer syndrome: Clinical variations and implications for counseling. International Journal of Cancer, 2012, 131, 367-376.	2.3	110
150	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. British Journal of Cancer, 2012, 106, 2016-2024.	2.9	27
151	Psychological distress in newly diagnosed colorectal cancer patients following microsatellite instability testing for Lynch syndrome on the pathologist's initiative. Familial Cancer, 2012, 11, 259-267.	0.9	16
152	Revertant Somatic Mosaicism by Mitotic Recombination in Dyskeratosis Congenita. American Journal of Human Genetics, 2012, 90, 426-433.	2.6	97
153	Rare Mutations in XRCC2 Increase the Risk of Breast Cancer. American Journal of Human Genetics, 2012, 90, 734-739.	2.6	172
154	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Human Mutation, 2012, 33, 690-702.	1.1	34
155	Mutation and association analyses of the candidate genes ESR1, ESR2, MAX, PCNA, and KAT2A in patients with unexplained MSH2-deficient tumors. Familial Cancer, 2012, 11, 19-26.	0.9	1
156	9 Genetisch is profetisch?. , 2012, , 91-99.		0
157	Abstract P3-02-09: Cost-effectiveness of screening with additional MRI for women with familial risk for breast cancer without a genetic predisposition. , 2012, , .		0
158	Young age and a positive family history of colorectal cancer are complementary selection criteria for the identification of Lynch syndrome. European Journal of Cancer, 2011, 47, 1407-1413.	1.3	11
159	Adding familial risk assessment to faecal occult blood test can increase the effectiveness of population-based colorectal cancer screening. European Journal of Cancer, 2011, 47, 1571-1577.	1.3	7
160	Validation study suggested no differential misclassification of self-reported mammography history in BRCA1/2 mutation carriers. Journal of Clinical Epidemiology, 2011, 64, 1434-1443.	2.4	6
161	PP 73 Prognostic relevance of constitutive expression of γ -H2AX in triple negative breast cancers. European Journal of Cancer, 2011, 47, S25.	1.3	0
162	Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncology, The, 2011, 12, 49-55.	5.1	232

#	ARTICLE	IF	CITATIONS
163	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011, 13, R110.	2.2	71
164	Constitutive expression of γ -H2AX has prognostic relevance in triple negative breast cancer. <i>Radiotherapy and Oncology</i> , 2011, 101, 39-45.	0.3	74
165	Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. <i>European Journal of Human Genetics</i> , 2011, 19, 870-874.	1.4	141
166	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. <i>British Journal of Cancer</i> , 2011, 104, 1356-1361.	2.9	7
167	Erfelijke darmkanker. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2011, 27, 20-26.	0.0	0
168	Shortened time interval between colorectal cancer diagnosis and risk testing for hereditary colorectal cancer is not related to higher psychological distress. <i>Familial Cancer</i> , 2011, 10, 51-57.	0.9	8
169	Body weight and risk of breast cancer in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 193-202.	1.1	59
170	A non-BRCA1/2 hereditary breast cancer sub-group defined by aCGH profiling of genetically related patients. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 425-436.	1.1	17
171	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. <i>Human Genetics</i> , 2011, 130, 685-699.	1.8	18
172	Group medical visits in the follow-up of women with a BRCA mutation: design of a randomized controlled trial. <i>BMC Women's Health</i> , 2011, 11, 39.	0.8	14
173	Recurrence and variability of germline <i>EPCAM</i> deletions in Lynch syndrome. <i>Human Mutation</i> , 2011, 32, 407-414.	1.1	137
174	Identification of candidate predisposing copy number variants in familial and early-onset colorectal cancer patients. <i>International Journal of Cancer</i> , 2011, 129, 1635-1642.	2.3	66
175	Spindle-Assembly Checkpoint and Gastrointestinal Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 1279-1280.	13.9	13
176	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	1.4	68
177	Common Genetic Variation at BARD1 Is Not Associated with Breast Cancer Risk in BRCA1 or BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 1032-1038.	1.1	16
178	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 4732-4747.	1.4	32
179	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	3.0	40
180	Lynch Syndrome-Associated Extracolonic Tumors Are Rare in Two Extended Families With the Same EPCAM Deletion. <i>American Journal of Gastroenterology</i> , 2011, 106, 1829-1836.	0.2	50

#	ARTICLE	IF	CITATIONS
181	Electronic reminders for pathologists promote recognition of patients at risk for Lynch syndrome: cluster-randomised controlled trial. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 653-659.	1.4	17
182	Physical activity and the risk of breast cancer in BRCA1/2 mutation carriers. <i>Breast Cancer Research and Treatment</i> , 2010, 120, 235-244.	1.1	79
183	Reliability of self-reported diagnostic radiation history in BRCA1/2 mutation carriers. <i>European Journal of Epidemiology</i> , 2010, 25, 103-113.	2.5	4
184	Female BRCA mutation carriers with a preference for prophylactic mastectomy are more likely to participate an educational-support group and to proceed with the preferred intervention within 2 years. <i>Familial Cancer</i> , 2010, 9, 213-220.	0.9	15
185	Constitutional submicroscopic genome imbalances in children with both cancer and a congenital anomaly. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 52.	1.0	0
186	EPCAM deletions and heritable MSH2 promoter methylation in Lynch syndrome. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 57.	1.0	0
187	Germline epimutation of the tumor suppressor gene PTPRJ in early onset familial colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 59.	1.0	1
188	The epigenetics of (hereditary) colorectal cancer. <i>Cancer Genetics and Cytogenetics</i> , 2010, 203, 1-6.	1.0	33
189	Noonan syndrome, the <i>SOS1</i> gene and embryonal rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 635-641.	1.5	33
190	Improving calculation, interpretation and communication of familial colorectal cancer risk: Protocol for a randomized controlled trial. <i>Implementation Science</i> , 2010, 5, 6.	2.5	9
191	Novel RUNX1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD/AML syndrome. <i>Leukemia</i> , 2010, 24, 242-246.	3.3	85
192	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	9.4	309
193	Psychosocial impact of Von Hippel Lindau disease: levels and sources of distress. <i>Clinical Genetics</i> , 2010, 77, 483-491.	1.0	35
194	BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 5265-5273.	0.8	166
195	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.4	169
196	Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2010, 19, 2886-2897.	1.4	60
197	Association of the Variants CASP8 D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 2859-2868.	1.1	37
198	Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. <i>Journal of Medical Genetics</i> , 2010, 47, 436-444.	1.5	495

#	ARTICLE	IF	CITATIONS
199	Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. <i>Journal of Medical Genetics</i> , 2010, 47, 464-470.	1.5	165
200	Common Genetic Variants and Modification of Penetrance of BRCA2-Associated Breast Cancer. <i>PLoS Genetics</i> , 2010, 6, e1001183.	1.5	85
201	Germline Epigenetic Silencing of the Tumor Suppressor Gene PTPRJ in Early-Onset Familial Colorectal Cancer. <i>Gastroenterology</i> , 2010, 139, 2221-2224.	0.6	46
202	TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. <i>Journal of Medical Genetics</i> , 2010, 47, 421-428.	1.5	254
203	Germline copy number variation and cancer risk. <i>Current Opinion in Genetics and Development</i> , 2010, 20, 282-289.	1.5	115
204	Educational-support groups for BRCA mutation carriers satisfy need for information but do not affect emotional distress. <i>Genetic Counseling</i> , 2010, 21, 423-37.	0.1	17
205	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	1.4	99
206	A simple method for co-segregation analysis to evaluate the pathogenicity of unclassified variants; BRCA1 and BRCA2 as an example. <i>BMC Cancer</i> , 2009, 9, 211.	1.1	57
207	The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 105-111.	1.0	28
208	Immunohistochemistry is not an accurate first step towards the molecular diagnosis of MUTYH-associated polyposis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2009, 454, 25-29.	1.4	8
209	Incidence of cancer in first-degree relatives of basal cell carcinoma patients. <i>Archives of Dermatological Research</i> , 2009, 301, 295-299.	1.1	3
210	Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH. <i>Breast Cancer Research and Treatment</i> , 2009, 116, 479-489.	1.1	124
211	No evidence that GATA3 rs570613 SNP modifies breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2009, 117, 371-379.	1.1	12
212	Genetic testing for Lynch syndrome in the first year of colorectal cancer: a review of the psychological impact. <i>Familial Cancer</i> , 2009, 8, 325-337.	0.9	17
213	Improvement of endometrial biopsy over transvaginal ultrasound alone for endometrial surveillance in women with Lynch syndrome. <i>Familial Cancer</i> , 2009, 8, 391-397.	0.9	63
214	In Lynch syndrome adenomas, loss of mismatch repair proteins is related to an enhanced lymphocytic response. <i>Histopathology</i> , 2009, 55, 414-422.	1.6	26
215	Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2. <i>European Journal of Human Genetics</i> , 2009, 17, 159-164.	1.4	21
216	Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3– exons of TACSTD1. <i>Nature Genetics</i> , 2009, 41, 112-117.	9.4	679

#	ARTICLE	IF	CITATIONS
217	Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. <i>British Journal of Cancer</i> , 2009, 100, 266-273.	2.9	392
218	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). <i>British Journal of Cancer</i> , 2009, 101, 2048-2054.	2.9	15
219	Plasma pre- β -HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2009, 1791, 714-718.	1.2	17
220	Chromosome 8q23.3 and 11q23.1 Variants Modify Colorectal Cancer Risk in Lynch Syndrome. <i>Gastroenterology</i> , 2009, 136, 131-137.	0.6	80
221	A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. <i>Breast Cancer Research</i> , 2009, 11, R8.	2.2	45
222	Genetic testing offered directly after the diagnosis of colorectal cancer: a pilot study on the reactions of patients. <i>Genetic Counseling</i> , 2009, 20, 317-25.	0.1	9
223	Most Patients with Colorectal Tumors at Young Age Do Not Visit a Cancer Genetics Clinic. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 1249-1254.	0.7	32
224	Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. <i>Human Mutation</i> , 2008, 29, 1282-1291.	1.1	782
225	Locus-specific databases and recommendations to strengthen their contribution to the classification of variants in cancer susceptibility genes. <i>Human Mutation</i> , 2008, 29, 1273-1281.	1.1	41
226	In silico analysis of missense substitutions using sequence-alignment based methods. <i>Human Mutation</i> , 2008, 29, 1327-1336.	1.1	181
227	Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance. <i>Human Mutation</i> , 2008, 29, 1292-1303.	1.1	54
228	Genetic evidence and integration of various data sources for classifying uncertain variants into a single model. <i>Human Mutation</i> , 2008, 29, 1265-1272.	1.1	169
229	Assessment of functional effects of unclassified genetic variants. <i>Human Mutation</i> , 2008, 29, 1314-1326.	1.1	93
230	Prediction and assessment of splicing alterations: implications for clinical testing. <i>Human Mutation</i> , 2008, 29, 1304-1313.	1.1	108
231	Assessing pathogenicity: overview of results from the IARC Unclassified Genetic Variants Working Group. <i>Human Mutation</i> , 2008, 29, 1261-1264.	1.1	79
232	Is early-onset microsatellite and chromosomally stable colorectal cancer a hallmark of a genetic susceptibility syndrome?. <i>International Journal of Cancer</i> , 2008, 122, 796-801.	2.3	11
233	Genome-wide linkage scan in Dutch hereditary non-BRCA1/2 breast cancer families identifies 9q21-q22 as a putative breast cancer susceptibility locus. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 947-956.	1.5	16
234	Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. <i>European Radiology</i> , 2008, 18, 931-938.	2.3	72

#	ARTICLE	IF	CITATIONS
235	Costs of breast cancer surveillance in BRCA mutation carriers. <i>European Journal of Cancer, Supplement</i> , 2008, 6, 94-95.	2.2	0
236	Predisposition to colorectal cancer: exploiting copy number variation to identify novel predisposing genes and mechanisms. <i>Cytogenetic and Genome Research</i> , 2008, 123, 188-194.	0.6	11
237	The impact of a false-positive MRI on the choice for mastectomy in BRCA mutation carriers is limited. <i>Annals of Oncology</i> , 2008, 19, 655-659.	0.6	36
238	Interpretation of Immunohistochemistry for Mismatch Repair Proteins is Only Reliable in a Specialized Setting. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1246-1251.	2.1	112
239	Familial Breast Cancer: Detection of Prevalent High-Risk Epithelial Lesions. , 2008, , 61-71.		2
240	Age at Menarche and Menopause and Breast Cancer Risk in the International BRCA1/2 Carrier Cohort Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 740-746.	1.1	63
241	Patients with an unexplained microsatellite instable tumour have a low risk of familial cancer. <i>British Journal of Cancer</i> , 2007, 96, 1605-1612.	2.9	41
242	Genomewide high-density SNP linkage analysis of non-BRCA1/2 breast cancer families identifies various candidate regions and has greater power than microsatellite studies. <i>BMC Genomics</i> , 2007, 8, 299.	1.2	26
243	Mapping of constitutional translocation breakpoints in renal cell cancer patients: identification of KCNP4 as a candidate gene. <i>Cancer Genetics and Cytogenetics</i> , 2007, 179, 11-18.	1.0	21
244	Tumor characteristics and detection method in the MRISC screening program for the early detection of hereditary breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 357-363.	1.1	40
245	Detecting Lynch syndrome by pathologists. <i>Verhandlungen Der Deutschen Gesellschaft FÃ¼r Pathologie</i> , 2007, 91, 104-11.	0.5	1
246	Optimizing the detection of hereditary non-polyposis colorectal cancer: An update. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 146-152.	0.6	6
247	Numerous high-risk epithelial lesions in familial breast cancer. <i>European Journal of Cancer</i> , 2006, 42, 2492-2498.	1.3	26
248	A substantial part of the fallopian tube is left after standard prophylactic bilateral salpingo-oophorectomy. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1940-1944.	1.2	10
249	Unfavorable pathological characteristics in familial colorectal cancer with low-level microsatellite instability. <i>Modern Pathology</i> , 2006, 19, 1624-1630.	2.9	10
250	Factors Affecting Sensitivity and Specificity of Screening Mammography and MRI in Women with an Inherited Risk for Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 109-119.	1.1	83
251	A DGGE system for comprehensive mutation screening ofBRCA1andBRCA2: application in a Dutch cancer clinic setting. <i>Human Mutation</i> , 2006, 27, 654-666.	1.1	75
252	Characterization of Familial Non-BRCA1/2 Breast Tumors by Loss of Heterozygosity and Immunophenotyping. <i>Clinical Cancer Research</i> , 2006, 12, 1693-1700.	3.2	31

#	ARTICLE	IF	CITATIONS
253	Surveillance of women at high risk for hereditary ovarian cancer is inefficient. <i>British Journal of Cancer</i> , 2006, 94, 814-819.	2.9	90
254	Very low prevalence of germline MSH6 mutations in hereditary non-polyposis colorectal cancer suspected patients with colorectal cancer without microsatellite instability. <i>British Journal of Cancer</i> , 2006, 95, 1678-1682.	2.9	12
255	Reply: Familial ovarian screening: how to address abnormal TVU findings and its influence on the efficacy of screening?. <i>British Journal of Cancer</i> , 2006, 95, 1126-1127.	2.9	1
256	Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of "easy to apply" probability models. <i>British Journal of Cancer</i> , 2006, 95, 757-762.	2.9	13
257	The decision evaluation scales. <i>Patient Education and Counseling</i> , 2005, 57, 286-293.	1.0	52
258	Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients. <i>Familial Cancer</i> , 2005, 4, 115-119.	0.9	60
259	Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations. <i>Journal of Medical Genetics</i> , 2005, 42, e20-e20.	1.5	51
260	Cost effectiveness of a new strategy to identify HNPCC patients. <i>Gut</i> , 2005, 54, 97-102.	6.1	78
261	Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). <i>Journal of Medical Genetics</i> , 2005, 42, e54-e54.	1.5	170
262	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. <i>Journal of Medical Genetics</i> , 2005, 42, 711-719.	1.5	360
263	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. <i>Breast Cancer Research</i> , 2005, 7, 1.	2.2	0
264	Randomized Trial of a Shared Decision-Making Intervention Consisting of Trade-Offs and Individualized Treatment Information for BRCA1/2 Mutation Carriers. <i>Journal of Clinical Oncology</i> , 2004, 22, 3293-3301.	0.8	106
265	Chromosome 3 Translocations and Familial Renal Cell Cancer. <i>Current Molecular Medicine</i> , 2004, 4, 849-854.	0.6	31
266	Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. <i>Clinical Genetics</i> , 2004, 65, 308-316.	1.0	62
267	Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. <i>British Journal of Cancer</i> , 2004, 90, 333-342.	2.9	69
268	Impact of BRCA1/2 testing and disclosure of a positive test result on women affected and unaffected with breast or ovarian cancer. <i>American Journal of Medical Genetics Part A</i> , 2004, 124A, 346-355.	2.4	64
269	More Differences Between HNPCC-related and Sporadic Carcinomas From the Endometrium as Compared to the Colon. <i>American Journal of Surgical Pathology</i> , 2004, 28, 706-711.	2.1	62
270	Very low incidence of microsatellite instability in rectal cancers from families at risk for HNPCC. <i>Clinical Genetics</i> , 2003, 63, 64-70.	1.0	20

#	ARTICLE	IF	CITATIONS
271	High Prevalence of Premalignant Lesions in Prophylactically Removed Breasts From Women at Hereditary Risk for Breast Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 41-45.	0.8	136
272	Atorvastatin Dose-Dependently Decreases Hepatic Lipase Activity in Type 2 Diabetes: Effect of sex and the LPC promoter variant. <i>Diabetes Care</i> , 2003, 26, 427-432.	4.3	50
273	Chromosome 3 translocations and the risk to develop renal cell cancer: a Dutch intergroup study. <i>Genetic Counseling</i> , 2003, 14, 149-54.	0.1	9
274	The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. <i>Cancer Research</i> , 2003, 63, 8153-7.	0.4	86
275	Atorvastatin, Diabetic Dyslipidemia, and Cognitive Functioning. <i>Diabetes Care</i> , 2002, 25, 1250-1251.	4.3	27
276	Decision Analysis of Prophylactic Surgery or Screening for BRCA1 Mutation Carriers: A More Prominent Role For Oophorectomy. <i>Journal of Clinical Oncology</i> , 2002, 20, 2092-2100.	0.8	87
277	Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158→Cys) Homozygotes Is Associated With Hyperinsulinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 294-299.	1.1	55
278	The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. <i>Journal of Internal Medicine</i> , 2002, 251, 148-155.	2.7	6
279	High fat intake in hyperlipidaemic patients is related to male gender, smoking, alcohol intake and obesity. <i>Netherlands Journal of Medicine</i> , 2001, 59, 16-22.	0.6	11
280	Corneal arcus: indicator for severity of coronary atherosclerosis?. <i>Netherlands Journal of Medicine</i> , 1999, 55, 184-187.	0.6	9
281	Atorvastatin increases low-density lipoprotein size and enhances high-density lipoprotein cholesterol concentration in male, but not in female patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 1999, 146, 167-174.	0.4	54
282	Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 7-14.	1.5	31
283	Hypertension treatment with doxazosin significantly decreases femoral wall thickness in males with hypercholesterolemia and peripheral atherosclerotic disease. <i>Atherosclerosis</i> , 1999, 144, 129-130.	0.4	0
284	High saturated fat intake in hyperlipidemic patients is related to male gender, smoking, alcohol intake and obesity. <i>Atherosclerosis</i> , 1999, 144, 130.	0.4	0
285	Gemfibrozil decreases autoantibodies against oxidized low-density lipoprotein in men with combined hyperlipidaemia. <i>Journal of Internal Medicine</i> , 1998, 243, 355-359.	2.7	8
286	Effects of atorvastatin on serum lipids of patients with familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 1998, 244, 143-147.	2.7	15
287	The IGF-I/IGFBP system in congenital partial lipodystrophy. <i>Clinical Endocrinology</i> , 1998, 49, 465-473.	1.2	11
288	Estrogen replacement decreases the level of antibodies against oxidized low-density lipoprotein in postmenopausal women with coronary heart disease. <i>Metabolism: Clinical and Experimental</i> , 1998, 47, 675-680.	1.5	32

#	ARTICLE	IF	CITATIONS
289	Growth hormone restores hepatic lipase mRNA levels but the translation is impaired in hepatocytes of hypothyroid rats. <i>Lipids and Lipid Metabolism</i> , 1997, 1345, 172-179.	2.6	6
290	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. <i>Clinical Chemistry</i> , 1997, 43, 1958-1964.	1.5	41
291	Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity. <i>Leukemia</i> , 1997, 11, 1377-1379.	3.3	60
292	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. <i>Journal of Internal Medicine</i> , 1997, 241, 151-155.	2.7	1
293	The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia. <i>Journal of Internal Medicine</i> , 1997, 241, 151-5.	2.7	0
294	Significance of various parameters derived from biological variability of lipoprotein(a), homocysteine, cysteine, and total antioxidant status. <i>Clinical Chemistry</i> , 1997, 43, 1958-64.	1.5	5
295	Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. <i>Metabolism: Clinical and Experimental</i> , 1996, 45, 680-685.	1.5	14
296	Hypertriglyceridemia Enhances Monocyte Binding to Endothelial Cells in NIDDM. <i>Diabetes Care</i> , 1996, 19, 1122-1125.	4.3	24
297	Lipoprotein(a) in Patients With Acute Cerebral Ischemia. <i>Stroke</i> , 1996, 27, 1231-1235.	1.0	35
298	Oral physiological magnesium supplementation for 6 weeks with 1 g/d magnesium oxide does not affect increased Lp(a) levels in hypercholesterolaemic subjects. <i>Magnesium Research</i> , 1996, 9, 129-32.	0.4	2
299	LETTERS TO THE EDITOR. <i>Journal of Internal Medicine</i> , 1995, 237, 603-605.	2.7	6
300	Monocytes from patients with combined hypercholesterolemia-hypertriglyceridemia and isolated hypercholesterolemia show an increased adhesion to endothelial cells in vitro: II. Influence of intrinsic and extrinsic factors on monocyte binding. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 374-378.	1.5	22
301	Growth hormone normalizes hepatic lipase in hypothyroid rat liver. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 669-671.	1.5	5
302	Hyperglycemia in the acute phase of stroke is not caused by stress.. <i>Stroke</i> , 1993, 24, 1129-1132.	1.0	126
303	The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. <i>Clinical Endocrinology</i> , 1992, 37, 79-87.	1.2	328
304	Patients with combined hypercholesterolemia-hypertriglyceridemia show an increased monocyte-endothelial cell adhesion in vitro: Triglyceride level as a major determinant. <i>Metabolism: Clinical and Experimental</i> , 1991, 40, 1119-1121.	1.5	34
305	The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia. <i>Journal of Internal Medicine</i> , 1990, 228, 261-266.	2.7	37
306	Growth hormone and thyroxine affect lipoprotein metabolism in hypothyroid and hypophysectomized rats. <i>Journal of Endocrinology</i> , 1990, 125, 403-407.	1.2	9

#	ARTICLE	IF	CITATIONS
307	Relationship between insulin-like growth factor-I and low-density lipoprotein cholesterol levels in primary hypothyroidism in women. <i>Journal of Endocrinology</i> , 1989, 123, 341-345.	1.2	21
308	Mutational Signature Analysis Reveals NTHL1 Deficiency to Cause a Multi-Tumor Phenotype Including a Predisposition to Colon and Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1